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Abstract
Pervasive Developmental Disorders (PDD) are chronic, lifelong disorders for which there is as yet
no effective cure, and medical management remains a challenge for clinicians. The current report
describes two patients affected by autistic disorder with associated gastrointestinal symptoms.
They received multiple doses of intravenous secretin for a six-month period and were assessed
with several specific outcome measures to evaluate drug effect.
The administration of secretin led to some significant and lasting improvement in only one case.
Gastroesophageal reflux may contribute to some of the behavioural problems and explain the
effect of secretin since its suppressive effect on gastric secretion is well known. It is also true that
autistic children with gastroesophageal reflux and a higher IQ could constitute a subtype which
responds to secretin administration and that could be labelled as a "gastrointestinal subtype".
Introduction
Pervasive Developmental Disorders (PDD) are chronic,
lifelong disorders for which there is as yet no effective
cure, and medical management remains a challenge for
clinicians. In spite of improvements in some associated
"problematic behaviors" with specific drugs, effective
medical treatment for the core language- and social cogni-
tion-related symptoms are not available because the biol-
ogy is not clearly understood and thus proper drug
treatment has not been possible [1]. However, significant
advances are being made towards understanding the
mechanisms of the disorders, and major challenges lie
ahead in evaluating the growing number of treatments for
autism and in integrating the results of research into treat-
ment and educational settings [2].
Since the experience of Horvath et al. [3] regarding secre-
tin administration, with their report of "a dramatic
improvement in the behavior of autistic children, mani-
fested by improved eye contact, alertness, expansion of
expressive language", and "relief of gastrointestinal symp-
toms", particular attention has been given to the potential
role of this biological agent on autism.
Interest in secretin is also justified by many studies that
have not only demonstrated the role of secretin as a classic
Published: 15 November 2005
Clinical Practice and Epidemiology in Mental Health 2005, 1:24 doi:10.1186/1745-0179-1-24
Received: 12 September 2005
Accepted: 15 November 2005
This article is available from: http://www.cpementalhealth.com/content/1/1/24
© 2005 Pallanti et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 6
(page number not for citation purposes)
Clinical Practice and Epidemiology in Mental Health 2005, 1:24 http://www.cpementalhealth.com/content/1/1/24hormone in the gastrointestinal system, but have firmly
supported its neuropeptide role [4], since secretin has
been shown to be capable of crossing the blood-brain bar-
rier [5] and of depolarizing nucleus tractus solitarius neu-
rons [6], activating brain regions including areas
abnormal in autism [7].
Although preliminary reports [8] on secretin application
initially generated enthusiasm, especially among parents
of children with PDD [9], recent controlled studies seem
to have dampened such enthusiasm (for a review, see
[10]), although there is still some space for discussion.
A study by Sandler et al. [11] showed the lack of benefits
in the treatment of core autistic symptoms with a single
dose of secretin, though Sandler recognized that his study
had several limitations: first, the follow-up period was
short-term; second, only a single dose was administered;
third, the diagnostic schedules used were not specific
enough to measure the response to treatment.
Owley et al. [12] also conducted a double-blind versus
placebo-controlled trial of porcine secretin for the treat-
ment of autism, reaching the conclusion that there is no
evidence of its efficacy.
Various studies conducted between 2000 and 2002 to
assess the efficacy of a single dose of secretin on autistic
features reported no significant effects [13]. All these stud-
ies adopted the DSM-IV criteria [14] and rating scales,
which mainly focus on the so-called core autistic symp-
toms (only Corbett et al., [13] also used gastrointestinal
measures to evaluate drug effects).
The wide range of autistic symptoms and their correlation
with gastrointestinal functions, eating behavior and social
interaction have not been focused on since Lightdale et al.
[15] reported, following a single-blind, open-label pilot
study, no effect of secretin in a five-week period on the
language and behavior of 20 children with autistic and
gastrointestinal symptoms.
Unis et al. [16] in a randomized double-blind, placebo-
controlled study, reported no evidence that either biologic
or synthetic secretin provided amelioration of symptoms
beyond placebo. Likewise, Levy et al. [17] came to the con-
clusion that a single dose of secretin is not effective in
changing behavior and communication in children with
PDD if compared to placebo. In a controlled setting [18],
parents of children with autism treated with a single dose
of secretin were unable to distinguish the short behavioral
effects of secretin from placebo.
These recent controlled studies seemed to spell the death
knell for an unproven treatment that captured the public's
imagination but found support in only a few positive
reports [19].
However, there are several limitations in these very appre-
ciable papers that leave some scope for us to report our
observations. First, most of the studies were performed
with a single infusion before the follow-up observational
period. There are only three studies conducted on small
samples [20] that report no evidence for the efficacy of
repeated doses of secretin on the symptoms, language or
cognitive functioning of children with autism. Second, the
(paradoxically) large size of the sample when studying
"categorized" autistic subjects leads to the risk of obtain-
ing ungeneralizable data because the category of autism
has a significant internal heterogeneity. Third, the wide
range of typologies and the degrees of severity of symp-
toms have only been distinguished in with or without a
widely defined condition labeled as "gastrointestinal
symptoms", and conclusions cannot be drawn about
hypothetically specific subtypes.
Methods
Given the controversial views surrounding the utility of
this hormone in the treatment of autism, we decided to
report our experience and considerations regarding two
children with a diagnosis of autistic disorder according to
DSM IV criteria. They were treated with secretin in order
to assess any kind of clinical improvement; particular
attention was devoted to the complexity of autistic eating
behavior.
Table 1: Participant details.
Case Age (yr) Weight (kg) IQ SB-IS Gastrointestinal symptoms Core symptoms
1 9 35 99 Reflux esophagitis Strict diet Severe abnormal relationships Severe abnormal 
verbal communication Inappropriate crying 
Rocking Repetitive movements Abnormal 
adaptation to change Rituals Sleep problems
2 7 25 86 Chronic diarrhoea Severe abnormal relationships Severe abnormal 
verbal communication Routine Obsessive 
interests Repetitive movements Self-injurious 
behaviour TantrumsPage 2 of 6
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The first subject was a 9-year-old male, with a body weight
of 35 kg, who was diagnosed as autistic at the age of two.
We were able to confirm the previous diagnosis, as lan-
guage and communication, social interaction and behav-
ioral core symptoms were present; associated problems
included a diet restriction and reflux esophagitis, and he
cried at inappropriate times. He had an IQ of 99.
The second subject was a 7-year-old male with a body
weight of 25 kg, who received his first diagnosis of autism
at about the age of two. His IQ was 86. We confirmed the
previous diagnosis, as he presented core symptoms and
associated problems, especially gastrointestinal symp-
toms in the form of chronic diarrhea. The two boys were
not taking other psychotropic medications during the
study.
These two subjects were recruited consecutively, in a
period when the data reported in literature about the
potential effectiveness of secretin were promising. No
other case was subsequently recruited (Table 1).
Procedure
The method consisted of a single-blind protocol. The
Stanford-Binet Intelligence Scale was employed before
treatment in order to evaluate intelligence based on stand-
ardized criteria [21].
After obtaining informed consent from the parents, we
administered aJapanese biological secretin, extracted from
the duodenum of pigs, each vial containing 50 CU of
secretin diluted in 2 ml. After a dose test of 1 CU over 1
minute, approximately 15 minutes prior to the full dose,
carried out in order to determine possible allergic reac-
tions, we administered the full intravenous secretin dos-
age of 2 CU/kg body-weight, given over a 1-minute period
in a volume of 0.2 ml/kg, for each injection. The aim of
the study was to administer 6 consecutive injections of
secretin, one every 4 weeks. Each administration was car-
ried out by an expert with proven experience of allergic
anaphylactic reactions and resuscitation methods,
because of the possibility that repeated use might result in
an allergic response. Assessment included: 1. the Behavio-
ral Summarized Evaluation [22], a 20-item scale that
seemed a valid clinical tool to assess behavioral modifica-
tions and the evolution of the symptoms of children with
autistic disorder; 2. the Clinical Global Impression Scale
[23], a 3-item scale (Severity of Illness, Global Improve-
ment, Efficacy Index) used to assess treatment response in
psychiatric patients. We used these to measure eight sepa-
rate features associated with autism (response to social
interaction, social inition, use of speech, types of repeti-
tive behavior, behavior problems, activity level, sleep
problems, and digestive problems) on a standardized,
seven-point Likert scale; 7 indicated "extremely ill", 4
"moderately ill" and 1 "normal" as regards Severity; 7
indicated "very much worse", 4 "no change", and 1 "very
much improved" as regards Global Improvement; the
Efficacy Index was measured on a four-point scale from
"none" to "outweighs therapeutic effect"; 3. the Child-
hood Autism Rating Scale [24] which is the most widely
used standardized instrument specifically designed to aid
in the diagnosis of autism in young children [25], which
includes 15 items (Relationships with People, Imitation,
Affect, Use of Body, Relation to Non-human Objects,
Adaptation to Environmental Change, Visual Responsive-
ness, Auditory Responsiveness, Near Receptor Respon-
siveness, Anxiety Reaction, Verbal Communication,
Nonverbal Communication, Activity Level, Intellectual
Functioning, and the Clinician's General Impression),
with a symptom severity rating that makes it possible to
use the scale for periodic monitoring and for assessing
long-term outcomes.
An evaluator absolutely blind to the type of protocol
assessed the children prior to and after the treatment, and
in the follow-up with intervals of one day, one week, four
weeks and six months after first treatment.
The pre-treatment assessment of the first boy yielded a
BSE score of 75 (with a score of 4 on item 18, regarding
eating disorders), a CGI score for severity of 6 and a CARS
score of 53. Then he received 6 intravenous injections,
one each month, each injection containing 75 CU of por-
cine secretin in 7 ml. He was evaluated with the three rat-
ing scales at intervals of one day, one week, and four
weeks from the beginning of treatment. In this case it was
possible to assess treatment response after six months
from first injection and a month after last injection.
The second case had a BSE score of 63 (with a score of 4
on item 18, regarding eating disorders), a CGI score for
severity of 6 and a CARS score of 52 in his pre-treatment
evaluation. He then received 2 intravenous injections with
an interval of a month, each injection containing 50 CU
of porcine secretin in 5 ml; then he was evaluated with the
three rating scales at intervals of one day, one week, and
four weeks from the beginning of treatment. Treatment
was suspended after the second injection since no effect
was reported. The follow-up at six months is not therefore
comparable but was conducted in any case since the sec-
ond injection had been administered.
Results
In the first case, at interval 1 (after 1 day) there was no sig-
nificant effect on the BSE, CGI (Severity was unchanged,
the Global Improvement score was 4, i.e. no change, and
the Efficacy Index score was 14, namely no treatment
effect with no side effects), or CARS scores; at interval 2 (aPage 3 of 6
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through behavioral rating scales – a slight amelioration of
his behavior, especially in alertness, expansion and efforts
toward communication, while eye contact did not
improve. In the same period parents reported an improve-
ment in his diet, an associated problem; he began eating
vegetables and pasta, which he had never wanted to eat
before. He had a BSE score of 71, with a reduction from 4
to 3 on items 5, 6, 18 and 19. The CGI score for Severity
did not change, the CGI score for Global Improvement
dropped to 3, and the Efficacy Index score was 10 (mild
effect with side effects that not interfere with the patient).
His CARS score was 51.5 with a reduction of score at item
1, Relationships with People (4 to 3.5) at item 11, Verbal
Communication (4 to 3.5), and at item 12, Nonverbal
Communication (4 to 3.5). In the fourth week, at interval
3, these positive findings seemed to be still present; this
was confirmed by a reduction of the BSE to 69, with a
reduction on item 18 (eating disorders) from 3 to 1. We
then proceeded with the second injection and since some
slight amelioration of core symptoms was seen over the
following four months we administered the other 4
planned intravenous injections. The symptoms follow-up
after 6 months revealed enduring significant improve-
ment with the same scores as at interval 3.
The second boy was evaluated prior to treatment and then
at intervals of one day, one week, four weeks and six
months after the treatment: no amelioration of core
symptoms was noticed at any time of treatment in either
eye contact, alertness or expansion of effort toward com-
munication. Clinical observation confirmed the absence
of positive results. We suspended treatment after the sec-
ond injection in compliance with the parents' wishes.
At intervals 1 (one day from first injection), 2 (one week)
and 3 (four weeks) there was no significant effect in the
BSE, CGI (Severity was unchanged, the Global Improve-
ment score was 4, i.e. no change and the Efficacy Index
score was 14, i.e. no treatment effect with no side effects)
or CARS (unvaried at 52) scores. Nor were any improve-
ments reported after six months (Table 2).
Conclusion
The administration of secretin in our two young patients
only led to some significant and enduring improvement
on core symptoms in one case, where we observed signif-
icant changes in associated problems such as difficulties
with toileting, sleeping and/or eating; laughing, crying or
giggling at inappropriate times; response to touch, light,
sound, taste or smells; unawareness of pain, heat or cold.
In particular, we observed an evident amelioration of eat-
ing behavior associated with a stable global behavioral
improvement.
This observation drew our attention to gastrointestinal
symptoms and eating behavior, not only to dieting (even
if in some cases it may be a relevant issue), in that the
importance of social interaction and eating behavior has
been pointed out by several studies [26]. Eating behavior
in autistic children seems to be an intriguing subject for
research, for several reasons:
a) because eating disorder, even when it is only consid-
ered as an associated problem, has important conse-
quences on the health of these patients;
b) because of the important interaction between eating
and social behavior; a recognized gastrointestinal disorder
may contribute to the determination of behavioral prob-
lems in autistic patients.
Autistic disorder has always been considered to be sub-
stantially a neurobiological problem, but we cannot
exclude different biological correlations, which could
open up new perspectives in research and treatment of the
disorder itself.
Besides, eating behavior is closely connected to attach-
ment social behavior (i.e.: sucking is an act that includes
Table 2: BSE score, CGI score for Severity, Global Improvement and Efficacy Index and CARS score at time 0, time 1 after one day, 
time 2 after one week, time 3 after four weeks and time 4 after six months.
Case BSE score CGI score S CARS score
0 1 2 3 4 0 1 2 3 4 0 1 2 3 4
1 75 71 69 69 69 6 6 6 6 6 53 53 51.5 51.5 51.5
GI 4 3 3 3
EI 14 10 10 10
2 63 63 63 63 64 6 6 6 6 6 52 52 52 52 52
GI 4 4 4 4
EI 14 14 14 14Page 4 of 6
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conducted on animals [28] show that hormones such as
oxytocin and vasopressin are involved in mediation at a
central level of attachment behavior. A possible influence
of secretin on autistic eating behavior could be mediated
by the formation of unknown neuropeptides that, per-
haps only in some children, finally have an influence on
the construction of social behavior.
On the other hand Horvath et al. [29] found gastro-
esophageal reflux and reflux esophagitis to be the most
frequently detected gastrointestinal abnormalities in chil-
dren with autistic disorder (69.4%). In our report the
child who improved with secretin treatment was the one
characterized by reflux esophagitis, while the child who
did not improve had chronic diarrhea but no gastric or
esophageal reflux. It is known that secretin has a suppres-
sive effect on gastric secretion [30]. Whether a low level of
secretin may contribute to the high prevalence of acid
reflux needs further investigations, but our report con-
firms the suggestion of Horvath & Perman [31] that gas-
trointestinal abnormalities may contribute to some of the
behavioral problems, and the presence of esophagitis cor-
relates well with the reported symptoms and may in part
explain the sudden irritability, crying behavior and diet
restriction as shown in our first case. In some way the
behavioral problems connected to gastrointestinal abnor-
malities could represent a form of challenging behavior
where a simple correction of dieting, or reflux reduction
could determine great behavioral improvements [32]. It is
also possible that autistic children with gastroesophageal
reflux and esophagitis and higher IQ constitute a subtype,
and probably respond better to secretin administration.
Following this line of investigation, recent studies on
autism suggest that there may be different subtypes of
autism, with special reference to the "gastrointestinal sub-
type" [19].
We are justified in thinking that a more precise definition
of each single case of autistic disorder would contribute to
delineating possible subtypes of autistic disorder, which is
currently a rather non-specific and over-inclusive diagnos-
tic category. It is also true that many studies [33] show an
increasing prevalence of PDD, especially among people
with intellectual disability; this could in part be due to a
better application of PDD DSM-IV criteria for autistic dis-
order or PDD not otherwise specified, and in part to
increasing interest in the concept of the autistic spectrum.
As a result of the relative non-specificity of the autistic dis-
order category, studies conducted on large samples may
have the bias of studying non-homogenous subjects. Con-
sequently, carefully described case reports could provide
orientation regarding possible subtypes, so these can be
described and recognized, and specific diagnostic criteria
developed. The higher IQ index, and the presence or
absence of some gastrointestinal symptoms in this case
could represent indications of a somewhat specific sub-
type of autistic disorder, susceptible to specific treatments.
To conclude, secretin is not an effective cure for autism, as
the extensive media attention suggested at the very begin-
ning. However, observation of its efficacy on specific tar-
gets permits a number of reflections: it is only by using
anecdotal reports and case observations showing reduc-
tion in the severity of specific symptom domains within
autistic disorders, recognizing different specific subtype
symptom domains, in order to elaborate good and valid
study design with accurate selection of patients and spe-
cific outcome measures that it will be possible to obtain
progress in the comprehension and cure of autism [34].
References
1. American Psychiatric Association: Diagnostic and Statistical Manual of
Mental Disorders 4th edition. Washington DC: APA; 1994:37-78.
Return to citation in text: [14]
2. Banks WA, Goulet M, Rusche JR, Niehoff ML, Bois R: Differential
transport of a secretin analog across the blood-brain and
blood-cerebrospinal fluid barriers of the mouse.  Journal of
Pharmacology and Experimental Therapeutics 2002, 302:1062-1069.
Return to citation in text: [5]
3. Barthelemy C, Adrien JL, Tanguay P, Garreau B, Fermanian J, Roux S,
Sauvage D, Lelord G: The Behavioral Summarized Evaluation:
validity and reliability of a scale for the assessment of autistic
behaviors.  Journal of Autism and Developmental Disorders 1990,
20:189-204. Return to citation in text: [22]
4. Carey T, Ratliff-Schaub B, Funk J, Weinle C, Myers M, Jenks J: Dou-
ble-blind placebo-controlled trial of secretin: effects on aber-
rant behavior in children with autism.  Journal of Autism and
Developmental Disorders 2002, 32:161-167. Return to citation in text:
[13]
5. Chey WY, Chang TM: Neural control of the release and action
of secretin.  Journal of Physiology and Pharmacology 2003:105-112.
Return to citation in text: [4]
6. Chez MG, Buchanan CP, Bagan BT, Hammer MS, McCarthy KS,
Ovrutskaya I, Nowinski CV, Cohen ZS: Secretin and autism: a
two-part clinical investigation.  Journal of Autism and Developmen-
tal Disorders 2000, 30:87-94. Return to citation in text: [13]
7. Chung I, Li P, Lee K, Chang T, Chey WY: Dual inhibitory mecha-
nism of secretin action on acid secretion in totally isolated,
vascularly perfused rat stomach.  Gastroenterology 1994,
107:1751-1758. Return to citation in text: [30]
8. Coniglio SJ, Lewis JD, Lang C, Burns TG, Subhani-Siddique R, Wein-
traub A, Schub H, Holden EW: A randomized, double-blind, pla-
cebo-controlled trial of single dose intravenous secretin as
treatment for children with autism.  Journal of Pediatrics 2001,
138:649-655. Return to citation in text: [19]
9. Coplan J, Souders MC, Mulberg AE, Belchic JK, Wray J, Jawad AF, Gal-
lagher PR, Mitchell R, Gerdes M, Levy SE: Children with autistic
spectrum disorders. II: parents are unable to distinguish
secretin from placebo under double-blind conditions.  Archives
of Disease in Childhood 2003, 88:737-739. Return to citation in text:
[18]
10. Corbett B, Khan K, Czapansky-Beilman D, Brady N, Dropik P, Gold-
man DZ, Delaney K, Sharp H, Mueller I, Shapiro E, Ziegler R: A dou-
ble blind, placebo-controlled crossover study investigating
the effect of porcine secretin in children with autism.  Clinical
Pediatry 2001, 40:327-331. Return to citation in text: [13]
11. Dogrukol-Ak D, Tore F, Tuncel N: Passage of VIP/PACAP/secre-
tin family across the blood-brain barrier: therapeutic effects.
Current Pharmaceutical Design 2004, 10:1325-1340. Return to citation
in text: [5]
12. Dunn-Geier J, Ho HH, Auersperg E, Doyle D, Eaves L, Matsuba C,
Orrbine E, Pham B, Whiting S: Effect of secretin on children with
autism: a randomized controlled trial.  Developmental Medicine
and Child Neurology 2000, 42:796-802. Return to citation in text: [13]Page 5 of 6
(page number not for citation purposes)
Clinical Practice and Epidemiology in Mental Health 2005, 1:24 http://www.cpementalhealth.com/content/1/1/24Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
13. Field D, Garland M, Williams K: Correlates of specific childhood
feeding problems.  Journal of Paediatrics and Child Health 2003,
39:299. Return to citation in text: [32]
14. Hollander E, Phillips AT, Yeh CC: Targeted treatments for symp-
tom domains in child and adolescent autism.  Lancet 2003,
362:732-734. Return to citation in text: [34]
15. Horvath K, Papadimitriou JC, Rabsztyn A, Drachenberg C, Tildon JT:
Gastrointestinal abnormalities in children with autistic dis-
order.  Journal of Pediatrics 1999, 135:559-563. Return to citation in
text: [29]
16. Horvath K, Stefanatos G, Sokolski KN, Watchtel R, Nabors L, Tildon
JT: Improved social and language skills after secretin admin-
istration in patients with autistic spectrum disorders.  Journal
of the Association for Academic Minority Physicians 1998, 9:9-15. Return
to citation in text: [3] [8]
17. Horvath K, Perman JA: Autism and gastrointestinal symptoms.
Current Gastroenterology Reports 2002, 4:251-258. Return to citation in
text: [31]
18. Insel TR: A Neurobiological Basis of Social Attachment.  Amer-
ican Journal of Psychiatry 1997, 6:726-735. Return to citation in text:
[27]
19. Insel TR, Winslow JT: Oxytocin and social attachment.  Giornale
Italiano di Psicopatologia 1997, 1:11-17. Return to citation in text: [28]
20. Kern JK, Espinoza E, Trivedi MH: The effectiveness of secretin in
the management of autism.  Expert Opinion on Pharmacotherapy
2004, 5:379-387. Return to citation in text: [10]
21. Kern JK, Van Miller S, Evans PA, Trivedi MH: Efficacy of porcine
secretin in children with autism and pervasive developmen-
tal disorder.  Journal of Autism and Developmental Disorders 2002,
32:153-160. Return to citation in text: [19]
22. La Malfa GP, Lassi S, Bertelli M, Salvini R, Placidi GF: Autism and
intellectual disability: a study of prevalence on a sample of
the Italian population.  Journal of Intellectual Disability Research
2004, 48:262-268. Return to citation in text: [33]
23. Lamson DW, Plaza SM: Transdermal secretin for autism – a
case report.  Alternative Medicine Review 2001, 6:311-313. Return to
citation in text: [19]
24. Levy SE: Repeated doses of porcine secretin did not improve
symptoms, language or cognitive functioning in children
with autism or autism spectrum disorder.  Evidence Based-Men-
tal Health 2002, 5:22. Return to citation in text: [20]
25. Levy SE, Souders MC, Wray J, Jawad AF, Gallagher PR, Coplan J, Bel-
chic JK, Gerdes M, Mitchell R, Mulberg AE: Children with autistic
spectrum disorders. I: comparison of placebo and single dose
of human synthetic secretin.  Archives of Disease in Childhood 2003,
88:731-736. Return to citation in text: [17]
26. Lightdale JR, Hayer C, Duer A, Lind-White C, Jenkins S, Siegel B, Elli-
ott GR, Heyman MB: Effects of intravenous secretin on lan-
guage and behavior of children with autism and
gastrointestinal symptoms: a single-blinded, open-label pilot
study.  Pediatrics 2001, 108:90. Return to citation in text: [15]
27. McQueen JM, Heck AM: Secretin for the treatment of autism.
The Annuals of Pharmacotherapy 2002, 36:305-311. Return to citation
in text: [10]
28. Molloy CA, Manning-Courtney P, Swayne S, Bean J, Brown JM, Murray
DS, Kinsman AM, Brasington M, Ulrich DD: Lack of benefit of
intravenous synthetic human secretin in the treatment of
autism.  Journal of Autism and Developmental Disorders 2002,
32:545-551. Return to citation in text: [13]
29. National Institute of Mental Health: CGI (Clinical Global Impres-
sion) Scale.  Psychopharmacological Bulletin 1985, 21:839-843. Return
to citation in text: [23]
30. Ng SS, Yung WH, Chow BK: Secretin as a neuropeptide.  Molec-
ular Neurobiology 2002, 26:97-107. Return to citation in text: [4]
31. Owley T, Steele E, Corsello C, Risi S, McKaig K, Lord C, Leventhal BL,
Cook EH: A double-blind, placebo-controlled trial of secretin
for the treatment of autistic disorder.  Medscape General Medi-
cine 1999, 6:2. Return to citation in text: [12]
32. Owley T, McMahon W, Cook EH, Laulhere T, South M, Mays LZ,
Shernoff ES, Lainhart J, Modhal CB, Corsello C, Ozonoff S, Risi S, Lord
C, Leventhal BL, Filipeck PA: Multisite, double-blind, placebo-
controlled trial of porcine secretin in autism.  Journal of the
American Academy of Child and Adolescent Psychiatry 2001,
40:1293-1299. Return to citation in text: [13]
33. Palermo MT, Curatolo P: Pharmacologic treatment of autism.
Journal of Child Neurology 2004, 19:155-164. Return to citation in text:
[1]
34. Patel NC, Yeh JY, Shepherd MD, Crismon ML: Secretin treatment
for autistic disorder: a critical analysis.  Pharmacotherapy 2002,
22:905-914. Return to citation in text: [10]
35. Perry R, Bangaru BS: Secretin in autism.  Journal of Child and Adoles-
cent Psychopharmacology 1998, 8:247-248. Return to citation in text:
[8]
36. Roberts W, Weaver L, Brian J, Bryson S, Emelianova S, Griffiths AM,
MacKinnon B, Yim C, Wolpin J, Koren G: Repeated doses of por-
cine secretin in the treatment of autism: a randomized pla-
cebo-controlled trial.  Pediatrics 2001, 107:71. Return to citation
in text: [20]
37. Sandler D, Sutton A, DeWeese J, Girardi A, Sheppard V, Bodfish J:
Lack of benefit of a single dose of synthetic human secretin
in the treatment of autism and pervasive developmental dis-
order.  New England Journal of Medicine 1999, 341:1801-1806. Return
to citation in text: [11]
38. Schopler E, Reichler RJ, DeVellis RF, Daly K: Toward objective
classification of childhood autism: Childhood autism rating
scale (CARS).  Journal of Autism and Developmental Disorders 1980,
10:91-103. Return to citation in text: [25]
39. Schopler E, Reichler RJ, DeVellis RF, Daly K: The Childhood Autism Rat-
ing Scale Los Angeles: Western Psychological Services; 1988.  Return
to citation in text: [24]
40. Sponheim E, Oftedal G, Helverschou SB: Multiple doses of secre-
tin in the treatment of autism: a controlled study.  Acta Paedi-
atrica 2002, 91:540-545. Return to citation in text: [20]
41. Stokstad E: Development. Desperate parents spark search for
new treatment.  Science 2001, 294:37. Return to citation in text:
[9]
42. Thorndike RL, Hagen EP, Sattler JM: The Stanford-Binet Intelligence
Scale, Fourth Edition: Guide for administering and scoring Chicago: River-
side; 1986.  Return to citation in text: [21]
43. Unis AS, Munson JA, Rogers SJ, Goldson E, Osterling J, Gabriels R,
Abbott RD, Dawson G: A randomized, double blind, placebo
controlled trial of porcine versus synthetic secretin for
reducing symptoms of autism.  Journal of the American Academy of
Child and Adolescent Psychiatry 2002, 41:1315-1321. Return to citation
in text: [16]
44. Vitousek KB, Ewald LS: Self-representation in eating disorders:
a cognitive perspective.  In The self in emotional disorders: cognitive
and psychodynamic perspectives Edited by: Segal Z, Blatt S. New York:
Guilford Press; 1993:221-257.  Return to citation in text: [26]
45. Volkmar FR, Lord C, Bailey A, Schultz RT, Klin A: Autism and per-
vasive developmental disorders.  Journal of Child Psychology and
Psychiatry 2004, 45:135-170. Return to citation in text: [2]
46. Welch MG, Keune JD, Welch-Horan TB, Anwar N, Anwar M, Ruggi-
ero DA: Secretin activates visceral brain regions in the rat
including areas abnormal in autism.  Cellular and Molecular Neu-
robiology 2003, 23:817-837. Return to citation in text: [7]
47. Yang B, Goulet M, Boismenu R, Ferguson AV: Secretin depolarizes
nucleus tractus solitarius neurons through activation of a
nonselective cationic conductance.  American Journal of Physiology
– Regulatory, Integrative and Comparative Physiology 2004, 286:927-934.
Return to citation in text: [6]Page 6 of 6
(page number not for citation purposes)
